According to a recent study, genetic testing can play a substantial role in medical management by uncovering changes in genes that are associated with an increased risk for hereditary cancers.
The conclusion of the research is based on a study that reviewed genetic testing results from 1.45 million individuals and found that nearly 25 per cent of "variants of uncertain significance" were subsequently reclassified -- sometimes as less likely to be associated with cancer, sometimes as more likely.
When variations from the norm are discovered in a gene, the variants are classified as "benign," "likely benign," "variant of uncertain significance," "likely pathogenic," or "pathogenic."
Dr. Theo Ross, senior author of the study, said, "If a variant is reclassified to being pathogenic, then it matters to the patient."
"For example, if they have a broken Lynch syndrome gene, then they need different care from their doctor such as having colonoscopies at an earlier age or more frequently, sometimes as often as every year. Or, if they have a broken BRCA gene, they may want to have prophylactic surgery or add MRI scans to their mammogram screening program," he explained.
Even a reclassification from "variant of uncertain significance" to "benign" can be important to a patient, providing them with peace of mind.
The typical gene contains about 27,000 base pairs, though some genes contain as many as 2 million. A large number of base pairs in each gene means there are myriad potential variations and there are many gaps in knowledge about the significance of individual variations. But knowledge about gene variants is constantly growing and evolving.
"The implications of this study are three-pronged. Physicians need to be aware of how rapidly knowledge about gene variants is advancing and that reclassifications are common. Labs need to review gene variant information on a regular basis and alert physicians to changes. Finally, patients and their family members need to be made aware of reclassifications by their physicians so they can make well-informed choices," Dr Ross said.
The findings appeared in the journal JAMA.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
